Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ross Campbell

MOHS-Micrographic Surgery Watkinsville, GA Medical Doctor

NPI 1215973482 CMS profile 146596

1180 Resurgence Dr, Suite 100, Watkinsville, GA 30677

Open in the dashboard

General payments

$3,443

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$128,789 paid to institutions, not to them · program years 2020–2023

Through program year 2025, Ross Campbell of Watkinsville, GA is reported in the CMS Open Payments database as having received $3,443 across 180 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $128,789 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 66th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $795 41
2024 General $717 34
2023 General $632 32
2022 General $391 19
2021 General $249 17
2020 General $45 2
2019 General $615 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ross Campbell
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Ross Campbell were reported at $795. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Ross Campbell MOHS-Micrographic Surgery median Middle half National median
2019 $615 $316 $106–$785 $163
2020 $45 $162 $68–$412 $114
2021 $249 $243 $87–$654 $132
2022 $391 $300 $102–$887 $149
2023 $632 $364 $125–$1,010 $160
2024 $717 $445 $142–$1,108 $164
2025 $795 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,221 76 payments
  2. Genzyme Corporation $739 29 payments
  3. Novartis Pharmaceuticals Corporation $248 10 payments
  4. Janssen Biotech, Inc. $170 6 payments
  5. Galderma Laboratories, L.P. $146 5 payments
  6. Pfizer Inc. $123 9 payments
  7. Regeneron Healthcare Solutions, Inc. $123 7 payments
  8. LEO Pharma Inc. $99 5 payments
  9. UCB, Inc. $71 3 payments
  10. Genentech USA, Inc. $67 4 payments
  11. Other $436 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,153 154 payments
  2. Education $290 26 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $774 30 payments
  2. RINVOQ $399 13 payments
  3. BOTOX $325 34 payments
  4. SKYRIZI $302 18 payments
  5. HUMIRA $184 8 payments
  6. TREMFYA $135 4 payments
  7. COSENTYX $128 5 payments
  8. DUPIXENT Immunology $125 6 payments
  9. EUCRISA $123 9 payments
  10. LIBTAYO $106 6 payments
  11. Other $1,268 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

3,076

Median for Dermatology: 534

Drug cost

$192,631

Median for Dermatology: $67,151

Branded share of claims

1.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erivedge Vismodegib Brand 12 $176,865
Cephalexin Generic 1,856 $6,235
Mupirocin Generic 517 $3,170
Doxycycline Hyclate Generic 426 $2,332
Fluorouracil Generic 16 $1,194
Ketoconazole Generic 32 $758
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 22 $677
Triamcinolone Acetonide Generic 51 $621
Minoxidil Generic 31 $347
Nystatin Generic 11 $162

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$1,634,811

Of which drugs: $214,168

Medicare patients

3,599

Average age 76

Services billed

12,235

1,656 women, 1,943 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 29%
Diabetes 24%
Chronic kidney disease 24%
Atrial fibrillation 20%
Cancer 17%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $142
$142 — —
TREMFYA
  • Janssen Biotech, Inc. $109
$109 — —
BOTOX
  • AbbVie, Inc. $91
$91 — —
DUPIXENT
  • GENZYME CORPORATION $80
$80 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record